Possible Long Targets Set For SBBP
Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded on May 26, 2015 and is headquartered in Lower Southampton, PA.
SHORT INTEREST
1.13M 08/15/19
Average Recommendation: BUY
Average Target Price: 13.71
P/E Current
7.53
P/E Ratio (with extraordinary items)
6.21
P/E Ratio (without extraordinary items)
6.51
SHORT INTEREST
1.13M 08/15/19
Average Recommendation: BUY
Average Target Price: 13.71
P/E Current
7.53
P/E Ratio (with extraordinary items)
6.21
P/E Ratio (without extraordinary items)
6.51
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.